Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Spectral Medical Inc. (T:EDT)

Business Focus: Pharmaceuticals (NEC)

Feb 28, 2024 07:30 am ET
Spectral Medical Provides February Tigris Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating...
Feb 21, 2024 04:00 pm ET
Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended...
Feb 15, 2024 07:41 am ET
Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in...
Feb 05, 2024 07:30 am ET
Spectral Medical Provides Early February Tigris Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating...
Jan 30, 2024 07:30 am ET
Spectral Medical Provides January Tigris Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating...
Jan 10, 2024 07:00 am ET
Spectral Medical Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating...
Dec 14, 2023 08:00 am ET
Spectral Medical Provides Tigris Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating...
Dec 04, 2023 08:00 am ET
Spectral Medical Provides November Tigris Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update for the month of November on the Company’s Tigris trial, a Phase 3...
Dec 01, 2023 08:00 am ET
Spectral Medical Announces CFO Departure
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Blair McInnis has provided notice of his resignation as Chief Financial...
Nov 14, 2023 08:55 am ET
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 15-16, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Nov 14, 2023 08:00 am ET
Spectral Medical Announces Publication of Tigris Trial Methods Paper and Simulation of Results
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the publication of its Tigris trial methods paper in Critical Care, which...
Nov 09, 2023 08:00 am ET
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter ended September 30, 2023 and...
Nov 07, 2023 08:00 am ET
Spectral Medical Provides Tigris Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has enrolled a total of 76 patients for the Company’s Tigris trial,...
Oct 16, 2023 08:00 am ET
Spectral Medical Announces Opening of Tigris Clinical Trial Site at the Mayo Clinic
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as its 19th...
Oct 03, 2023 08:00 am ET
Spectral Medical Provides Tigris Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the progress of its Tigris trial including patient enrollment...
Oct 02, 2023 08:00 am ET
Spectral Medical Provides Board Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that John Nosenzo will be stepping down from Spectral Medical’s Board of...
Sep 13, 2023 07:00 am ET
Spectral Medical Supports World Sepsis Day
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to support World Sepsis Day today. World Sepsis Day is an initiative by the...
Sep 08, 2023 08:13 am ET
Spectral Medical Featured in New Episode of ‘The Balancing Act’ Airing on Lifetime TV Focused on Endotoxic Septic Shock
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce a new episode of The Balancing Act focused on advancing therapeutic...
Sep 07, 2023 01:44 pm ET
CORRECTION – Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing
Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced ”bought deal” private placement of 9.0% convertible unsecured senior notes due November 1, 2026 (the “Notes") of the...
Sep 07, 2023 07:00 am ET
Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing
Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced ”bought deal” private placement of 9.0% convertible unsecured senior notes due November 1, 2026 (the “Notes") of the...
Aug 22, 2023 07:00 am ET
Spectral Medical Inc. Announces Upsizing of Previously Announced Bought Deal Convertible Note Financing to C$5.5M
Spectral Medical Inc. (TSX: EDT) (the “Company” or “Spectral”), is pleased to announce that in connection with its previously announced bought deal private placement financing (the “Offering”), the Company and Paradigm Capital Inc. (the...
Aug 16, 2023 11:12 am ET
Spectral Medical Highlights New Episode of ‘The Balancing Act’ Airing on Lifetime TV Focused on Endotoxic Shock
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today highlighted a new episode of The Balancing Act with a segment focused on advancing...
Aug 10, 2023 08:00 am ET
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2023 and...
Aug 10, 2023 07:00 am ET
Spectral Medical Inc. Announces C$5 Million Bought Deal Convertible Note Financing
Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to announce that it has entered into an agreement with Paradigm Capital Inc. (the “Underwriter”), in connection with a bought deal private placement of convertible notes...
Jul 25, 2023 08:00 am ET
Spectral Medical Announces Tigris Clinical Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has enrolled a total of 69 patients for the Company’s Tigris trial,...
Jul 05, 2023 08:00 am ET
Spectral Medical Announces the Opening of Three Additional Tigris Clinical Trial Sites
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the opening of three new clinical trials sites, the University of Alabama at...
Jun 27, 2023 08:00 am ET
Spectral Medical Appoints Former FDA Director, Dr. David W. Feigal, Jr., to Its Board of Directors
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has appointed Dr. David W. Feigal, Jr., M.D., M.P.H., to its Board...
Jun 20, 2023 08:00 am ET
Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company’s follow-on study designed to...
Jun 08, 2023 04:00 pm ET
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual and Special Meeting of shareholders (the...
May 30, 2023 08:00 am ET
Spectral Medical Provides Update on Favorable Tigris Clinical Trial Enrollment
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company’s follow-on study designed to...
May 24, 2023 08:00 am ET
Spectral Medical Hosts Successful Investigator Meeting; Expected to Help Bolster Enrollment Activities
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today reported hosting an investigator meeting in Charlotte, North Carolina on May 17 - 18,...
May 12, 2023 08:00 am ET
Spectral Medical Announces First Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2023 and...
May 04, 2023 04:00 pm ET
Spectral Medical Inc. Announces Director Resignation
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Mr. Jim Funk has tendered his resignation from the Board of Directors...
Apr 18, 2023 08:00 am ET
Spectral Medical Announces Positive Results of EUPHAS-2 Clinical Trial Evaluating PMX in Critically Ill Endotoxemic Septic Shock Patients
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced positive results in EUPHAS-2, an observational study in Italy using...
Apr 06, 2023 08:00 am ET
Spectral Medical Announces Investor Update Conference Call
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced details for the Company’s 2023 Investor Update conference call. Chris Seto,...
Mar 24, 2023 08:00 am ET
Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December...
Mar 09, 2023 08:00 am ET
Spectral Medical Announces the Opening of Two Additional Tigris Clinical Trial Sites
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the opening of two clinical trials sites, the Medical University of South...
Feb 22, 2023 09:00 am ET
Spectral Medical To Present At Microcap Rodeo's Annual Winter Wonderland- Best Ideas Virtual Investor Conference Today
TORONTO, ON / ACCESSWIRE / February 22, 2023 / Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has been invited to present at MicroCap Rodeo's Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023.
Jan 12, 2023 07:30 am ET
Spectral Medical Provides Update on Tigris Clinical Trial and Other Business Developments
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided a business update focusing on Tigris, the Company’s follow-on study designed...
Dec 13, 2022 07:30 am ET
Spectral Medical Announces Strategic Joint Venture With Infomed to Accelerate Commercialization of Dimi and Sami Dialysis Devices
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Nov 10, 2022 08:00 am ET
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Nov 02, 2022 09:29 am ET
Spectral Medical Inc. Closes $10.8 Million Public Offering and Concurrent Private Placement
Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced prospectus offering of units (the “Units”) of the Company (the “Unit Offering”) and concurrent private placement (the...
Oct 06, 2022 05:00 pm ET
Spectral Medical Inc. Announces Pricing of Previously Announced Offering
Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that further to its previously proposed prospectus offering of units (the “Unit Offering”) of the Company (the “Units”) and private placement (the “Note Offering”...
Oct 05, 2022 04:25 pm ET
Spectral Medical Inc. Announces Proposed Public Offering of Units and Private Placement of Notes
Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce the launch of a proposed prospectus offering of units (the “Unit Offering”) of the Company (the “Units”) and private placement (the “Note Offering” and...
Oct 04, 2022 09:21 am ET
Spectral Medical Provides Update on Tigris Clinical Trial
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Aug 18, 2022 08:00 am ET
Spectral Announces FDA Approval to Add Up to 10 Additional Tigris Clinical Trial Sites
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Aug 12, 2022 08:00 am ET
Spectral Announces Second Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Aug 08, 2022 08:00 am ET
Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical and Distribution Partner Marathon Medical Awarded Contract to Provide SAMI Dialysis Devices to the US Department of Veterans
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jul 26, 2022 08:00 am ET
Spectral Medical’s Chief Medical Officer, Dr. John Kellum, to be the Featured Speaker in Webinar Hosted by Sepsis Alliance
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jul 20, 2022 08:00 am ET
Spectral Medical Provides Update on Tigris Clinical Trial
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jul 14, 2022 10:00 am ET
Spectral Medical Highlights From Vicenza Course 2022
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jul 13, 2022 08:00 am ET
Spectral Medical to Participate at the Benzinga All Access event on July 15, 2022
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jul 11, 2022 08:00 am ET
US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ (“PMX”) for the Treatment of Endotoxemic Septic Shock
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that the US Food & Drug Administration (“FDA”) has granted Breakthrough...
Jun 21, 2022 04:20 pm ET
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jun 14, 2022 07:30 am ET
Spectral and Dialco Announce Dr. John Kellum to be Featured as Keynote Lecturer at the 40th Vicenza Course on AKI and CRRT 2022
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy...
Jun 13, 2022 07:30 am ET
Spectral Medical Announces Adoption of SAMI Device by the Largest Inpatient Dialysis Provider in South Florida
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
May 16, 2022 07:30 am ET
Spectral Medical Announces Appointment of Leading Industry Executive Sam Amory as Dialco President
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
May 13, 2022 10:00 am ET
Spectral to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. ("Dialco"), today announced that Chris Seto, CEO and Dr. Jon Kellum, CMO of Spectral Medical, have been invited to present at the Spring Into Action - Best Ideas Investor Conference,
May 13, 2022 07:30 am ET
Spectral Announces First Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Apr 27, 2022 08:00 am ET
Spectral to Present at Investor Summit Group's Q2 In-person Conference on May 3rd in NYC
Toronto, Ontario--(Newsfile Corp. - April 27, 2022) - Spectral Medical Inc. (TSX: EDT) ("Spectral" or the "Company"), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. ("Dialco"), today announced that Chris Seto, CEO and Dr. Jon Kellum, CMO of Spectral Medical will be presenting at The Q2 Investor Summit, hosted by the Investor Summit Group, being held on May 3-4, 2022 at The Westin New York Grand Central.
Mar 24, 2022 07:30 am ET
Spectral Announces Fourth Quarter and Fiscal 2021 Results and Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Mar 21, 2022 07:30 am ET
Spectral Medical Announces Appointment of Blair McInnis as CFO
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Mar 16, 2022 08:00 am ET
Dialco Medical Announces Formation of Medical Advisory Board to Support the Continued Development of DIMI Device
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”), has formed a Medical Advisory Board to support in guiding the DIMI usability trial and continued...
Mar 04, 2022 08:00 am ET
Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Feb 11, 2022 08:00 am ET
Spectral Medical Reports Progress on Tigris Clinical Trial
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jan 31, 2022 08:00 am ET
Spectral Medical Announces U.S. FDA Approval of DIMI Trial Protocol Amendment
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”) has received approval of a protocol amendment to its DIMI usability trial from the United States...
Dec 03, 2021 08:00 am ET
Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that Chris Seto, Chief Executive Officer of Spectral Medical, is scheduled to present at the SNN Network...
Nov 30, 2021 08:00 am ET
Spectral Medical Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will host a conference call at 2:00 PM EST on Thursday, December 2, 2021, to provide a clinical...
Nov 29, 2021 08:00 am ET
Spectral Medical Announces U.S. FDA Approval of Tigris Trial Protocol Amendment to Expand Inclusion Criteria
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Nov 15, 2021 09:10 am ET
Spectral to Present at the Q4 Investor Summit on November 16th
Toronto, Ontario--(Newsfile Corp. - November 15, 2021) - Spectral Medical Inc. (TSX: EDT) ("Spectral" or the "Company") and its wholly-owned subsidiary, Dialco Medical Inc. ("Dialco"), today announced that management will present at the Q4 Investor Summit, hosted by the Investor Summit Group, being held virtually on November 16-17, 2021.
Nov 12, 2021 08:00 am ET
Spectral Announces Third Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Oct 25, 2021 08:00 am ET
Spectral to Present at the Benzinga Global Small Cap Conference on October 27, 2021
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that Chris Seto, Chief Executive Officer of Spectral, will present at the Benzinga Global Small Cap...
Oct 20, 2021 08:00 am ET
Spectral and Dialco Announce Dr. John Kellum to Be Featured as Keynote Lecturer at the 39th Vicenza Course on AKI and CRRT
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), are pleased to announce that Dr. John Kellum, the Company’s CMO, will be featured as the keynote lecturer at the virtual...
Sep 13, 2021 08:00 am ET
Spectral Medical’s CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day and Sepsis Awareness Month
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and endotoxemic septic shock, as well as commercializing a new proprietary platform targeting the renal...
Aug 23, 2021 08:00 am ET
Spectral Medical Announces its Participation at Upcoming Investor Conferences
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing diagnostic and therapeutic options for septic shock as well as commercializing a new proprietary platform targeting the renal replacement...
Aug 13, 2021 08:00 am ET
Spectral Announces Second Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Aug 09, 2021 08:00 am ET
Spectral Medical Announces Internal Reorganization of its Wholly Owned Subsidiary Dialco Medical to Enhance Operations and Accelerate Commercialization
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced an internal reorganization to strengthen the core competencies and management of its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”). In connection with the...
Jul 28, 2021 08:00 am ET
Spectral Medical Inc. Provides Tigris Clinical Trial Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing diagnostic and therapeutic options for septic shock as well as commercializing a new proprietary platform targeting the renal replacement...
Jul 27, 2021 09:05 am ET
Spectral Medical Inc. Closes $10 Million Offering of Units
Spectral Medical Inc. (TSX: EDT) ("Spectral" or the "Company"), a late stage theranostic company advancing therapeutic options for sepsis and septic shock as well as commercializing a new proprietary platform targeting the renal replacement...
Jul 21, 2021 09:25 am ET
Spectral Medical Inc. Announces $10 Million Offering
Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that further to its previously announced overnight marketed public offering of units of the Company (the “Units”), Paradigm Capital Inc. (the “Lead Underwriter”)...
Jul 20, 2021 04:27 pm ET
Spectral Medical Inc. Announces Overnight Marketed Offering
Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce the launch of a proposed overnight marketed public offering of units of the Company (the “Units”) of up to $10 million (the “Offering”). The Offering will be...
Jun 07, 2021 08:25 am ET
Dialco Medical Inc. Engages CROMSOURCE as Contract Research Organization Partner for DIMI IDE Trial
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jun 04, 2021 01:00 pm ET
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock as well as commercializing a new proprietary platform targeting the renal replacement therapy...
May 14, 2021 08:00 am ET
Spectral Announces First Quarter Results and Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
May 11, 2021 07:00 am ET
Spectral Medical to Present at the Q2 Virtual Investor Summit on May 17th
Toronto, Canada--(Newsfile Corp. - May 11, 2021) - Spectral Medical Inc. (TSX: EDT) ("Spectral" or the "Company"), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. ("Dialco"), today announced that Chris Seto, Chief Executive Officer of Spectral, and Dr. John Kellum, Chief Medical Officer of Spectral, are scheduled to present at the Q2 Virtual Investor Summit at 1:15 PM, Eastern Time, on Monday, May 17, 2021.
May 05, 2021 08:00 am ET
Spectral Medical’s Wholly-Owned Subsidiary Dialco Medical Announces DIMI Usability Trial Posted on the ClinicalTrials.gov Website
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that the DIMI usability trial, run by its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco''), is registered and posted on the ClinicalTrials.gov website under the...
Apr 15, 2021 08:00 am ET
Spectral Medical Announces Exercise of Warrants for Gross Proceeds of Approximately $3.0 Million
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Apr 08, 2021 08:00 am ET
Spectral Medical’s Dialco Medical Announces 20 Year Exclusive License Agreement for DIMI Hemodialysis System in the United States and Canada
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”) has entered into an expanded, long-term licensing agreement with Infomed SA (“Infomed”) for the DIMI...
Mar 31, 2021 08:00 am ET
Spectral Medical’s Wholly-Owned Subsidiary Dialco Medical Announces Receipt of Health Canada License for DIMI
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”) has obtained its Health Canada license for the DIMI RRT system. As per the Health Canada license, DIMI...
Mar 26, 2021 08:00 am ET
Spectral Announces Fourth Quarter and Fiscal 2020 Results and Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Mar 08, 2021 08:00 am ET
Spectral Medical Announces the Appointment of Chris Seto to CEO
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced the appointment of Chris Seto to Chief Executive Officer (“CEO”), effective April 1, 2021. In his new role, Mr. Seto will continue to serve as the Company’s Chief...
Mar 04, 2021 08:00 am ET
Spectral Medical Engages Crescendo Communications to Provide Investor Relations Services in the United States
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Mar 02, 2021 08:00 am ET
Spectral Medical to participate at the upcoming H.C. Wainwright Global Life Sciences Conference
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Feb 23, 2021 08:00 am ET
Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical has been Granted FDA IDE Authorization to Conduct a Trial of DIMI for Home Hemodialysis Use
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”), has been granted Investigational Device Exemption (IDE) authorization by the United States Food and...
Feb 01, 2021 08:00 am ET
Spectral Medical Appoints Dr. John Kellum as Chief Medical Officer
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jan 11, 2021 08:00 am ET
Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Jan 06, 2021 08:00 am ET
Spectral Medical to Present at the SNN Network Canada Virtual Event on January 7, 2021
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Nov 27, 2020 08:00 am ET
Spectral Medical to Host Virtual Investor Day on December 4, 2020
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Nov 24, 2020 08:00 am ET
Spectral Medical Announces that its wholly owned subsidiary Dialco Medical has received MDSAP certification
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Nov 11, 2020 04:00 pm ET
Spectral Announces Third Quarter Results
Spectral Medical Inc., (“Spectral” or the “Company”)(TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock and targeting the renal replacement therapy (“RRT”) market through its wholly owned...
Nov 11, 2020 08:00 am ET
Spectral Medical Announces Report on Clinical Implementation of SAMI Amid COVID-19 Published in the Journal of Blood Purification
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement...
Nov 03, 2020 07:00 am ET
Spectral and Dialco Sponsored Symposiums at the 38th Vicenza Course on AKI and CRRT
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical In. (“Dialco”), are pleased to announce the following sponsored symposiums at the virtual 38th Vicenza Course on AKI and CRRT from Monday,...
Sep 08, 2020 08:00 am ET
Spectral to Present at H.C. Wainwright & Co. 22nd Annual Global Investment Conference
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), announced today that Dr. Paul Walker, Spectral’s Chief Executive Officer and Chris Seto, Spectral’s Chief Operating and Chief Financial Officer will be presenting virtually at the H.C....
Aug 31, 2020 07:00 am ET
U.S. FDA Grants 510(k) Clearance for Spectral’s DIMI
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”) has been granted 510(k) clearance by the United States Food and Drug Administration (“FDA")  for DIMI...
Aug 14, 2020 08:00 am ET
Spectral Announces Second Quarter Results
Spectral Medical Inc., (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2020. Financial Review...
Aug 10, 2020 08:00 am ET
US FDA Approves Spectral Medical’s Protocol Amendment for TIGRIS
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that the United States Federal Food and Drug Agency (“FDA”) has approved a...
Aug 05, 2020 08:00 am ET
Spectral Medical Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided a corporate update on its Tigris trial, COVID-19 initiatives, EAA launch, and...
Aug 04, 2020 08:00 am ET
Spectral Medical Inc. Appoints John E. Nosenzo to its Board of Directors
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it has appointed John E. Nosenzo as an independent director, effective...
Jul 06, 2020 07:00 am ET
Spectral Medical Inc. Files Base Shelf Prospectus
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it filed a final short form base shelf prospectus (the “Base Shelf...
Jun 26, 2020 11:34 am ET
Spectral Medical Inc. Files Preliminary Base Shelf Prospectus
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it has filed a preliminary short form base shelf prospectus with the...
Jun 18, 2020 11:15 am ET
Spectral Medical Inc. Closes Previously Announced $5.1 Million Public Offering of Units
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it has closed its previously announced marketed public offering of...
Jun 05, 2020 08:11 am ET
Spectral Announces Voting Results of Annual General and Special Meeting and Promotion of Chris Seto to Chief Operating Officer
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that, at the annual general and special meeting (the “Meeting”) of...
May 27, 2020 04:13 pm ET
Spectral Medical Inc. Announces Proposed Public Offering of Units
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it has filed a preliminary short form prospectus (the “Prospectus”)...
May 15, 2020 08:00 am ET
Spectral Announces First Quarter Results
Spectral Medical Inc., (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2020. Financial Review Revenue for the...
Apr 28, 2020 07:00 am ET
Spectral Medical Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, released an update today on the impact of COVID-19 on the Company’s business, the measures...
Apr 20, 2020 07:00 am ET
Health Canada Issues an Interim Order for Spectral Medical’s PMX to Treat COVID-19 Patients
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Health Canada has issued an Interim Order expanding the already...
Apr 14, 2020 08:00 am ET
US FDA Approves an Investigational Device Exemption for Spectral Medical PMX to Treat COVID-19 Patients Suffering from Septic Shock
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce that the United States Federal Food and Drug Agency (“FDA”) has...
Apr 02, 2020 08:00 am ET
Spectral Provides Update on the Commercial Development of its SAMI Device for Continuous Renal Replacement Therapy
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to provide an update on the commercialization activities at Dialco Medical Inc....
Mar 27, 2020 08:00 am ET
SPECTRAL ANNOUNCES FOURTH QUARTER AND FISCAL 2019 RESULTS
Spectral Medical Inc., (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2019. Financial Review...
Mar 12, 2020 03:34 pm ET
SPECTRAL MEDICAL INC. WITHDRAWS PUBLIC OFFERING
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that, in light of current market conditions, it is withdrawing its...
Mar 05, 2020 04:05 pm ET
Spectral Medical Inc. Announces Proposed Public Offering of Common Shares
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, announced today that it has filed a preliminary short form prospectus (the “Prospectus”)...
Feb 04, 2020 07:00 am ET
Baxter and Spectral Medical Announce Exclusive Distribution Agreement for Blood Filter in U.S. and Canada
Baxter International Inc. (NYSE:BAX), a leading global medical products company, and Spectral Medical Inc. (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a distribution...
Nov 14, 2019 08:00 am ET
Spectral Announces Third Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the third quarter ended September 30, 2019....
Sep 24, 2019 08:00 am ET
Spectral Medical Launches the Tigris Trial
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the first Investigator Meeting for the Tigris...
Sep 18, 2019 11:01 am ET
Spectral Medical Inc. Opens the Market
TORONTO, Sept. 18, 2019 /CNW/ - Dr. Paul Walker, CEO & President, Spectral Medical Inc. (EDT), joined Dani Lipkin, Innovation Sector Head, Capital Formation, Toronto Stock Exchange and TSX Venture Exchange, to open the market to celebrate 25 years listed on Toronto Stock Exchange. Spectral Medical Inc. is a therapeutic development company focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. Spectral Medical Inc. commenced trading on Toronto Stock Exchange on June 6, 1994.
Sep 18, 2019 08:00 am ET
Spectral Medical Rings the Bell at the Opening of the Toronto Stock Exchange
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that members of the Board of Directors and...
Aug 15, 2019 08:00 am ET
Spectral Announces Second Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2019....
Aug 08, 2019 08:00 am ET
Spectral Medical Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, is providing a corporate update on its activities both for the...
Jul 17, 2019 08:00 am ET
Spectral Medical Announces New Chief Financial Officer
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, is pleased to announce the addition of Chris Seto as the Company’s...
Jun 05, 2019 03:07 pm ET
Spectral Announces Voting Results of Annual and Special Meeting
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that, at the annual and special meeting (the...
May 09, 2019 08:00 am ET
Spectral Announces First Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2019....
Mar 28, 2019 08:00 am ET
Spectral Announces Fourth Quarter and Fiscal 2018 Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter and for the year ended December 31,...
Mar 20, 2019 08:00 am ET
Spectral Expands its Renal Replacement Therapy Development Program to Include the Home Dialysis Market
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announces that it has entered into an agreement...
Feb 21, 2019 08:00 am ET
Spectral Announces First Orders of Its Proprietary CRRT Machine
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announces that, following the execution of the...
Feb 19, 2019 08:00 am ET
Spectral Announces Approval of Tigris Trial by the US FDA
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announced that the Tigris clinical trial has been...
Jan 22, 2019 08:00 am ET
Spectral Announces Distribution Agreement for its Proprietary CRRT Machine
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announces the completion of a distribution...
Dec 19, 2018 08:00 am ET
Spectral to Attend the 37th Annual J.P. Morgan Healthcare Conference
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, announced today that the Company will participate in the...
Dec 17, 2018 08:00 am ET
Spectral Announces Results of a Face-to-Face meeting with the U.S. FDA
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announces the result of a favourable face-to-face...
Nov 26, 2018 08:00 am ET
Spectral Announces Publication of the post hoc analysis of EUPHRATES trial in Intensive Care Medicine
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announces that a new paper reporting on the...
Nov 14, 2018 08:00 am ET
Spectral Announces Third Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the third quarter ended September 30, 2018....
Oct 31, 2018 08:00 am ET
Spectral to enhance the Sales and Marketing team in Canada
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announced the appointment of Mr. Anjan Sidhu as...
Oct 18, 2018 08:00 am ET
Spectral Announces Presentation at the European Society of Intensive Care Medicine Oct 22nd and Publication of Overall Results of the EUPHRATES trial in JAMA
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announced that the first publication reporting data...
Oct 01, 2018 08:00 am ET
Spectral Enters into Technology Transfer Transaction And Provides Update on US FDA Process
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announced that it has entered into a technology...
Aug 14, 2018 08:00 am ET
Spectral Announces Second Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2018....
Jul 18, 2018 08:01 am ET
Spectral Announces Successful Manufacturing Audit of Toray by the US FDA
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announced that Toray Industries, manufacturer of...
Jun 07, 2018 04:00 pm ET
Spectral Announces Voting Results of Annual Meeting
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual meeting (the...
May 30, 2018 08:00 am ET
Spectral Provides Corporate Update
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today provided the following corporate update....
May 11, 2018 08:00 am ET
Spectral Announces First Quarter Results
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2018....
Apr 23, 2018 08:00 am ET
Spectral Medical Completes $5.3 Million Financing
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that it has...
Mar 29, 2018 08:00 am ET
Spectral Announces Fourth Quarter and Fiscal 2017 Results
TORONTO, March 29, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter...
Mar 19, 2018 08:00 am ET
US Food and Drug Administration (FDA) provides communication to Spectral  
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first targeted treatment for patients with septic shock today announced that the FDA has determined that more evidence is required to...
Feb 15, 2018 08:00 am ET
Spectral Announces Health Canada Approval of Its Proprietary Stand-Alone Pump for CRRT and Hemoperfusion
TORONTO, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX:EDT), a Phase III company developing a treatment for patients with endotoxemic septic shock, today announced that Health Canada (HC) has approved, under Licence No. 100541, the Spectral...
Feb 01, 2018 08:00 am ET
Spectral Medical Announces the Appointment of Chief Financial Officer
TORONTO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX:EDT), a Phase III company developing a treatment for patients with endotoxemic septic shock, today announced that Richard Wieland II has been appointed as interim CFO.
Dec 18, 2017 08:00 am ET
FDA Grants 510(k) Clearance for Spectral's Proprietary Stand-Alone Pump
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the United States Food and Drug Administration ("FDA") has granted 510(k) clearance for the Spectral Apheresis Machine ("SAM") for use in continuous renal replacement therapy ("CRRT") and therapeutic plasma exchange ("TPE"). The Company has also submitted final documentation seeking approval of SAM from Health Canada and anticipates a decision in the first half of 2018.
Dec 18, 2017 07:58 am ET
FDA Grants 510(k) Clearance for Spectral's Proprietary Stand-Alone Pump
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the United States Food and Drug Administration ("FDA") has granted 510(k)...
Dec 13, 2017 08:00 am ET
Spectral to Launch Toraymyxin(TM)/EAA(TM) in Canada in Q1 2018
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the company has entered into a distribution agreement with CASTER MEDICAL SYSTEM ("CMS") to launch Toraymyxin(TM) ("PMX") and EAA(TM) in Canada commencing in the first quarter of 2018. CMS's experienced sales team will promote the products in all parts of the country, with Spectral's team contributing scientific and marketing support. CMS is specialized in selling high value medical devices (disposables
Dec 13, 2017 07:58 am ET
Spectral to Launch Toraymyxin(TM)/EAA(TM) in Canada in Q1 2018
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that the company has entered into a distribution agreement with CASTER MEDICAL...
Nov 14, 2017 08:00 am ET
Spectral Announces Third Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced its unaudited financial results for the third quarter ended September 30, 2017.
Nov 14, 2017 07:58 am ET
Spectral Announces Third Quarter Results
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced its unaudited financial results for the third quarter ended September 30, 2017. Financial...
Oct 31, 2017 08:00 am ET
Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for Toraymyxin(TM)
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced the results of its recent meeting with the United States Food and Drug Administration ("FDA") concerning the status of its PMA application for Toraymyxin(TM).
Oct 31, 2017 07:58 am ET
Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for Toraymyxin(TM)
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced the results of its recent meeting with the United States Food and Drug Administration ("FDA") concerning...
Oct 18, 2017 08:00 am ET
Spectral Announces Retirement of Chief Financial Officer
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced that Tony Businskas will be retiring as the Executive Vice President and CFO of the Company on January 31, 2018, after 12 years of service to the Company.
Oct 18, 2017 07:58 am ET
Spectral Announces Retirement of Chief Financial Officer
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced that Tony Businskas will be retiring...
Oct 04, 2017 12:10 pm ET
Spectral Presents Key EUPHRATES Trial Data at the Canadian Critical Care Forum
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, announced that, in a special plenary session this afternoon being held at the 2017 Canadian Critical Care Forum in Toronto, Dr. Paul Walker, President & CEO of Spectral, will deliver a presentation titled "Treatments for Septic Shock : New Insights from the EUPHRATES Trial." The presentation will be available afterwards on the Company's website at www.spectraldx.com.
Sep 21, 2017 08:00 am ET
Spectral Provides Regulatory Update on Its PMA Submission for Toraymyxin(TM)
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced that, pursuant to the acceptance by the United States Food and Drug Administration ("FDA") of its PMA submission for Toraymyxin(TM) for filing on July 20, 2017, it has been engaged in an ongoing interactive review process with the FDA. Based on the filing acceptance date of July 20, 2017, the Company expects to receive more detailed feedback from the FDA on its PMA submission in the fourth quarter of this year.
Sep 21, 2017 07:58 am ET
Spectral Provides Regulatory Update on Its PMA Submission for Toraymyxin(TM)
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock, today announced that, pursuant to the acceptance by the United States Food and Drug Administration ("FDA") of its PMA...
Aug 11, 2017 08:00 am ET
Spectral Announces Second Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2017.
Aug 11, 2017 07:58 am ET
Spectral Announces Second Quarter Results
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2017. Financial Review...
Jul 24, 2017 08:00 am ET
FDA Accepts Spectral's PMA for Toraymyxin(TM) for Review
Spectral Medical Inc. (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock, today announced that the United States Food and Drug Administration ( "FDA") has accepted its rolling PMA application for Toraymyxin(TM) ("PMX") for review.
Jul 24, 2017 07:58 am ET
FDA Accepts Spectral's PMA for Toraymyxin(TM) for Review
Spectral Medical Inc. (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock, today announced that the United States Food and Drug Administration ( "FDA") has accepted its rolling PMA application for...
Jun 12, 2017 08:00 am ET
Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRT
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that on June 14, 2017 at 11:30 am EDT (5:30 pm CEST), a special lecture entitled "Critical Care Nephrology Cases Presentation - Results of the EUPHRATES Trial", will be presented by Professor Massimo Antonelli at the 35th annual Vicenza Course on AKI (acute kidney injury) and CRRT(continuous renal replacement therapy) in Vicenza, Italy. The Vicenza Course, organized by Professor Claudio Ronco, is one of the most
Jun 12, 2017 07:58 am ET
Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRT
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that on June 14, 2017 at 11:30 am EDT (5:30 pm CEST), a special lecture entitled...
Jun 01, 2017 12:57 pm ET
Spectral Announces Voting Results of Annual Meeting
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual meeting (the "Meeting") of...
Jun 01, 2017 12:57 pm ET
Spectral Announces Voting Results of Annual Meeting
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that at the annual meeting (the "Meeting") of shareholders of the Corporation ("Shareholders") that was held yesterday, all six nominees for the board were elected, the voting results of which are as follows:
May 30, 2017 08:00 am ET
Spectral Files Final PMA Module for Toraymyxin(TM) With FDA
Spectral Medical Inc., ("Spectral" or the "Company"), (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that it has submitted the fourth and final module of its PMA application to the United States Food and Drug Administration ("FDA") based on further analysis of the EUPHRATES trial - a randomized, blinded trial of patients in endotoxemic septic shock comparing use of Toraymyxin(TM) ("the PMX cartridge") versus sham hemoperfusion.
May 30, 2017 07:58 am ET
Spectral Files Final PMA Module for Toraymyxin(TM) With FDA
Spectral Medical Inc., ("Spectral" or the "Company"), (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that it has submitted the fourth and final module of...
May 12, 2017 08:00 am ET
Spectral Announces First Quarter Results
Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2017.
May 12, 2017 07:58 am ET
Spectral Announces First Quarter Results
Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2017....
Apr 26, 2017 08:00 am ET
Spectral Expands Distribution of EAA(TM) In the Middle and Far East and in Europe
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced the renewal and expansion of its exclusive distribution agreements with Toray Medical Co., Ltd. (TMC) and ESTOR SpA (ESTOR) for Spectral's rapid test for the assessment of endotoxin activity in human whole blood (EAA(TM)). The diagnostic will be sold primarily in conjunction with the Toraymyxin(TM) (PMX) hemoperfusion cartridge, which removes endotoxin from the bloodstream and is
Apr 26, 2017 07:58 am ET
Spectral Expands Distribution of EAA(TM) In the Middle and Far East and in Europe
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced the renewal and expansion of its exclusive...
Mar 30, 2017 08:00 am ET
Spectral Announces Fourth Quarter and Fiscal 2016 Results
Spectral Medical Inc. (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter and for the year ended December 31, 2016.
Mar 30, 2017 07:58 am ET
Spectral Announces Fourth Quarter and Fiscal 2016 Results
Spectral Medical Inc. (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its financial results for the fourth quarter and for the year ended December 31,...
Mar 07, 2017 08:00 am ET
U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it has received approval of the third module of its rolling PMA submission from the United States Food and Drug Administration ("FDA) for Toraymyxin(TM). The third PMA module details the device description and principles of operation and all manufacturing processes, including risk management and quality system integration.
Mar 07, 2017 07:58 am ET
U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it has received approval of the third module of...
Feb 23, 2017 08:00 am ET
Spectral to File Final PMA Module With the FDA for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock
Spectral Medical Inc., ("Spectral" or the "Company"), (TSX: EDT) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it plans to file the fourth of four modules of its premarket approval application (PMA) submission, containing the clinical study report, with the FDA for Toraymyxin(TM) early in the second quarter of this year. The EUPHRATES trial is the first in North America to use a companion diagnostic, the EAA, in the area of sepsis to select patients most likely to benefit from the
Feb 23, 2017 07:58 am ET
Spectral to File Final PMA Module With the FDA for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock
Spectral Medical Inc., ("Spectral" or the "Company"), (TSX:EDT) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it plans to file the fourth of four modules of...
Dec 14, 2016 08:00 am ET
Spectral Voluntarily Delists From OTCQX
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT)(OTCQX: EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that after a detailed review of the trading volume, costs and administrative requirements related to maintaining the Company's listing on the OTCQX, it has voluntarily delisted its Common shares from the OTCQX effective January 1, 2017. Spectral's Common shares will continue to be listed on the Toronto Stock Exchange.
Dec 14, 2016 07:58 am ET
Spectral Voluntarily Delists From OTCQX
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that after a detailed review of the...
Dec 05, 2016 08:00 am ET
Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT) (OTCQX: EDTXF) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced the appointment of Dr. Masayuki Kaneko as the Toray Industries, Inc. ("Toray") representative on its Board of Directors.
Dec 05, 2016 07:58 am ET
Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) (OTCQX:EDTXF) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced the...
Nov 11, 2016 08:00 am ET
Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results
Spectral Medical Inc., (TSX: EDT) (OTCQX: EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced next steps in its development program for Toraymyxin(TM) (PMX) and released financial results for the third quarter ended September 30, 2016.
Nov 11, 2016 07:58 am ET
Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results
Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced next steps in its development program for Toraymyxin™ (PMX) and...
Oct 03, 2016 08:02 am ET
Spectral Announces Clinical Trial Results
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT)(OTCQX: EDTXF) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced the top line results of its Phase III pivotal trial which enrolled a total of 450 patients, including a pre specified population of 243 patients with a high multiple organ dysfunction score ("MODS") either treated with two Toraymyxin(TM) columns or given two shams (the per protocol group).
Oct 03, 2016 08:02 am ET
Spectral Announces Clinical Trial Results
 Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF) a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced the top line results of its Phase...
Sep 20, 2016 03:18 pm ET
IIROC Trade Resumption - EDT
TORONTO, Sept. 20, 2016 /CNW/ - Trading resumes in:
Sep 20, 2016 02:09 pm ET
IIROC Trading Halt - EDT
TORONTO, Sept. 20, 2016 /CNW/ - The following issues have been halted by IIROC:
Sep 20, 2016 02:05 pm ET
Spectral Responds to Recent Trading Activity
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT) (OTCQX: EDTXF), at the request of IIROC on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release, they are not aware of any corporate developments that would cause the recent movement in the Company's share price.
Sep 20, 2016 02:05 pm ET
Spectral Responds to Recent Trading Activity
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT) (OTCQX:EDTXF), at the request of IIROC on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release, they are not aware of any corporate developments that...
Sep 07, 2016 08:00 am ET
Spectral Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT)(OTCQX: EDTXF) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City.
Sep 07, 2016 07:58 am ET
Spectral Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT)(OTCQX:EDTXF) a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from endotoxemic septic shock, today announced it will be featured as a...